Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Nov;33(6):1194-1202.
doi: 10.3904/kjim.2016.426. Epub 2017 Dec 15.

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome

Sang Kyun Sohn  1 , Joon Ho Moon  1 , In Hee Lee  1 , Jae Sook Ahn  2 , Hyeoung Joon Kim  2 , Joo Seop Chung  3 , Ho Jin Shin  3 , Sung Woo Park  3 , Won Sik Lee  4 , Sang Min Lee  4 , Hawk Kim  5 , Ho Sup Lee  6 , Yang Soo Kim  6 , Yoon Young Cho  7 , Sung Hwa Bae  7 , Ji Hyun Lee  8 , Sung Hyun Kim  8 , Ik Chan Song  9 , Ji Hyun Kwon  10 , Yoo Jin Lee  1
Affiliations
Comparative Study

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome

Sang Kyun Sohn et al. Korean J Intern Med. 2018 Nov.

Abstract

Background/aims: This study evaluated the role of hypomethylating agents (HMA) compared to best supportive care (BSC) for patients with high or very-high (H/VH) risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System.

Methods: A total of 279 H/VH risk MDS patients registered in the Korean MDS Working Party database were retrospectively analyzed.

Results: HMA therapy was administered to 205 patients (73.5%), including 31 patients (11.1%) who then received allogeneic hematopoietic cell transplantation (allo-HCT), while 74 patients (26.5%) received BSC or allo-HCT without HMA. The 3-year overall survival (OS) rates were 53.1% ± 10.7% for allo-HCT with HMA, 75% ± 21.7% for allo-HCT without HMA, 17.3% ± 3.6% for HMA, and 20.8% ± 6.9% for BSC groups (p < 0.001). In the multivariate analysis, only allo-HCT was related with favorable OS (hazard ratio [HR], 0.356; p = 0.002), while very poor cytogenetic risk (HR, 5.696; p = 0.042), age ≥ 65 years (HR, 1.578; p = 0.022), Eastern Cooperative Oncology Group performance status (ECOG PS) 2 to 4 (HR, 2.837; p < 0.001), and transformation to acute myeloid leukemia (AML) (HR, 1.901; p = 0.001) all had an adverse effect on OS.

Conclusion: For the H/VH risk group, very poor cytogenetic risk, age ≥ 65 years, ECOG PS 2 to 4, and AML transformation were poor prognostic factors. HMA showed no benefit in terms of OS when compared to BSC. Allo-HCT was the only factor predicting a favorable long-term outcome. The use of HMA therapy did not seem to have an adverse effect on the transplantation outcomes. However, the conclusion of this study should be carefully interpreted and proven by large scale research in the future.

Keywords: Higher risk; Hypomethylating agent; Myelodysplasia; Revised International Prognostic Scoring System.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1.
Figure 1.
Overall survival curves according to treatment plan. Allo-HCT, allogeneic hematopoietic cell transplantation; OS, overall survival; HMA, hypomethylating agents; BSC, best supportive care.
Figure 2.
Figure 2.
Incidence of acute (A) and chronic (B) graft-versus-host disease (GVHD). HMA, hypomethylating agents; aGVHD, acute GVHD; cGVHD, chronic GVHD.
See this image and copyright information in PMC

References

    1. Greenberg PL, Stone RM, Bejar R, et al. Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw. 2015;13:261–272. - PMC - PubMed
    1. Oran B, Popat U, Andersson B, Champlin R. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013;13 Suppl 2:S282–S288. - PubMed
    1. Sekeres MA. The euphoria of hypomethylating agents in MDS and AML: is it justified? Best Pract Res Clin Haematol. 2013;26:275–278. - PubMed
    1. Steensma DP. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes? Best Pract Res Clin Haematol. 2012;25:443–451. - PubMed
    1. Kim Y, Kim IH, Kim HJ, et al. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes. Int J Hematol. 2014;99:635–643. - PubMed

Publication types

MeSH terms

LinkOut - more resources